For HIV-positive patients with end-stage renal disease receiving chronic dialysis, lamivudine at 25 mg once daily provides drug exposure equivalent to 150 mg twice daily in similar patients with normal renal function, researchers report.
Dr. Charles B. Hicks and colleagues from Duke University Medical Center, Durham, North Carolina, evaluated the steady-state pharmacokinetics of lamivudine in 11 HIV-positive patients with end-stage renal disease. Nine of the patients were receiving hemodialysis and the other two were receiving continuous ambulatory peritoneal dialysis.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!